Clik here to view.
Novartis drug Signifor approved in the EU as the first medication to treat...
* Reuters is not responsible for the content in this press release. Wed Apr 25, 2012 Novartis International AG / Novartis drug SigniforR approved in the EU as the first medication to treat patients...
View ArticleClik here to view.
Cushing’s on Capitol Hill: Cushing’s Awareness Challenge
Earlier this year, I got this email: Good morning Mary: I hope everything is well. I would like to invite you to join us at the Rare Disease Congressional Caucus briefing scheduled for April 2013. The...
View ArticleClik here to view.
Know Your Number
English: “Dr. Harvey Cushing,” oil on canvas, by the American artist Edmund Tarbell. Courtesy of the Dittrick Medical History Center. (Photo credit: Wikipedia) From my email: As an advocate for...
View ArticleClik here to view.
Research on Cushing’s Disease Presented at ENDO 2013
Researchers at PHAR, in conjunction with experts from Novartis Pharmaceuticals Corporation, presented the results of several studies on Cushing’s disease at the Endocrine Society’s 95th Annual Meeting...
View ArticleClik here to view.
Cushing Disease: A Multidisciplinary Treatment Update
Share this info with your endo in case he/she missed it! This activity is intended for endocrinologists, primary care physicians, nurses, nurse practitioners, and pharmacists. The goal of this activity...
View ArticleClik here to view.
No High-Quality Studies for Cushing’s Drugs
By Salynn Boyles, Contributing Writer, MedPage Today Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN,...
View ArticleClik here to view.
Pituitary ACTH Hypersecretion (Cushing’s Disease) – Pipeline Review, H2 2013
DUBLIN — Research and Markets (http://www.researchandmarkets.com/research/h78zrm/pituitary_acth) has announced the addition of the “Pituitary ACTH Hypersecretion (Cushing’s Disease) – Pipeline Review,...
View ArticleClik here to view.
Through The Art Of Makeup, People With Rare Pituitary Disorders Now Have...
Did you know that applying contour powder on certain areas of your face, like the outer rim of the jaw, along the hairline or along the hollows of the cheek, can help make enlarged features less...
View ArticleClik here to view.
Rare Diseases, Loud Voices
This year, Novartis is adopting the theme, “Rare Diseases, Loud Voices,” is offering content aimed at helping to amplify the voices of patients, families and caregivers impacted by rare diseases...
View ArticleClik here to view.
The Voices of Cushing’s Disease
The perspectives of individuals living with Cushing’s disease, their caregivers and advocates. In creating this series, Novartis hoped to shine a spotlight on key factors involved in living with...
View ArticleClik here to view.
Pituitary Tumor Roundtable – Part One: A Focus on Diagnosis
Novartis is committed to supporting the pituitary community and continues to address the evolving needs of patients and caregivers. In this video, a multidisciplinary panel discusses the diagnosis of...
View ArticleClik here to view.
Global Cushing’s Syndrome Market Size 2015
Cushing’s as money makers for drug companies :( ~~~ Steroidogenesis inhibitors were responsible for approximately 28% of total drug sales in the 6MM in 2013, equating to around $50m. As a consequence...
View ArticleClik here to view.
Osilodrostat maintained cortisol control in Cushing’s syndrome
Osilodrostat, a drug that normalized cortisol in 89% of patients with Cushing’s syndrome who took it during a phase II study, continued to exert a sustained benefit during a 31-month extension phase....
View ArticleLong-acting Signifor Has Similar Safety Profiles as Twice-daily Treatment in...
A long-acting, once-a-month treatment of Signifor (pasireotide) normalized cortisol levels in 40% of patients with Cushing’s disease whose disease had recurred after surgery, or who were not candidates...
View ArticleOsilodrostat Continues to Show Promise for Cushing’s Disease
NEW ORLEANS — The investigational drug osilodrostat (Novartis) continues to show promise for treating Cushing’s disease, now with new phase 3 trial data. The data from the phase 3, multicenter,...
View ArticleCushing’s Disease—Monthly Injection Is Good Alternative to Surgery
Written by Kathleen Doheny with Maria Fleseriu, MD, FACE, and Vivien Herman-Bonert, MD Cushing’s disease, an uncommon but hard to treat endocrine disorder, occurs when a tumor on the pituitary gland,...
View ArticleSlow and Steady With Osilodrostat Best in Cushing’s Disease
Gradual dose escalation had fewer adverse events, same therapeutic benefit, as quicker increases by Kristen Monaco, Staff Writer, MedPage Today May 27, 2021 A more gradual increase in oral...
View ArticleCushing’s Syndrome Diagnostic and Treatment Market See Huge Growth for New...
I don’t know if there’s anything of interest here – or the cost – but possibly useful to someone. Cushing’s Syndrome Diagnostic and Treatment Market research report is the new statistical data source...
View Article
